A LinkedIn post from Orasis Pharmaceuticals highlights the company’s planned presence at the SECO 2026 optometry meeting, where its team will be available at Booth 133. The post points to educational programming focused on pilocarpine, including a breakfast symposium led by several optometrists and a poster session on concentration‑dependent effects of low‑concentration pilocarpine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content suggests Orasis is continuing to build clinical and scientific visibility around its pilocarpine‑based approach in front of an audience of eye‑care professionals. For investors, this type of activity may indicate ongoing commercial preparation and KOL engagement in the presbyopia market, which could support future product adoption and strengthen the company’s positioning against larger ophthalmic competitors.